nvm i re-read their analysis and risk and it state:
We see Immunotherapies as the key variable in our valuation over the next 12 months. Should COR-1 (Phase II) and COR-2 (Phase Ib) both achieve positive clinical results in their current trials, and assuming no significant change in the viral shedding rate released with the COR-1 interim results, our valuation rises to 58c/share. With respect to downside risk, should both clinical programs fail, we would ascribe a zero value to Immunotherapies (at least until such time as the two HPV pre-clinical programs enter the clinic), and our valuation would fall to 39c/share.
however, the result is not negative either, so idk should i be bothered to invest here atm or not LOL
- Forums
- ASX - By Stock
- AVR
- Ann: Response to Aware Query
Ann: Response to Aware Query, page-14
Featured News
Add AVR (ASX) to my watchlist
(20min delay)
|
|||||
Last
$11.30 |
Change
-0.650(5.44%) |
Mkt cap ! $238.8M |
Open | High | Low | Value | Volume |
$11.71 | $11.83 | $11.24 | $346.8K | 29.94K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 90 | $11.05 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$11.50 | 50 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 90 | 11.050 |
2 | 228 | 11.000 |
1 | 25 | 10.990 |
1 | 500 | 10.960 |
1 | 1000 | 10.820 |
Price($) | Vol. | No. |
---|---|---|
11.500 | 50 | 1 |
11.800 | 200 | 1 |
12.000 | 5023 | 2 |
12.010 | 191 | 1 |
12.020 | 1000 | 1 |
Last trade - 16.10pm 28/10/2024 (20 minute delay) ? |
Featured News
AVR (ASX) Chart |